Table of Contents

1.0 Description of the Procedure, Product, or Service ......................................................... 1

1.1 Definitions ......................................................................................................................... 2

1.1.1 Aberrant Behavior .......................................................................................................... 2

1.1.2 Abstinence ..................................................................................................................... 2

1.1.3 Clinical Laboratory Improvement Amendments (CLIA) .................................................... 2

1.1.4 Definitive Urine Drug Test ............................................................................................ 2

1.1.5 Gas chromatography/mass spectrometry (GC/MS) ......................................................... 2

1.1.6 Immunoassay (IA) ......................................................................................................... 2

1.1.7 Mass Spectrometry and Liquid Chromatography ......................................................... 2

1.1.8 Point of Care Testing (POCT) ...................................................................................... 2

1.1.9 Presumptive Urine Drug Test ....................................................................................... 3

1.1.10 Reflex Testing ............................................................................................................... 3

1.1.11 Specimen Validity Test .............................................................................................. 3

2.0 Eligibility Requirements ..................................................................................................... 3

2.1 Provisions ......................................................................................................................... 3

2.1.1 General ........................................................................................................................ 3

2.1.2 Specific ......................................................................................................................... 3

2.2 Special Provisions .............................................................................................................. 4

2.2.1 EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age ................................................................. 4

2.2.2 EPSDT does not apply to NCHC beneficiaries .............................................................. 5

2.2.3 Health Choice Special Provision for a Health Choice Beneficiary age 6 through 18 years of age ................................................................. 5

3.0 When the Procedure, Product, or Service Is Covered .......................................................... 5

3.1 General Criteria Covered .................................................................................................. 5

3.2 Specific Criteria Covered ................................................................................................ 5

3.2.1 Specific criteria covered by both Medicaid and NCHC ................................................. 5

3.2.1.1 Toxicity .................................................................................................................... 5

3.2.1.2 Treatment of substance use disorder ....................................................................... 6

3.2.1.3 Treatment of Chronic Pain ..................................................................................... 7

3.2.1.4 Reflex Testing ......................................................................................................... 8

3.2.1.5 Direct to Definitive Testing .................................................................................... 8

3.2.1.6 Definitive Testing to Confirm a Negative Presumptive Result .................................. 8

3.2.1.7 Definitive Testing to Confirm a Presumptive Positive ............................................ 8

3.3 Medicaid Additional Criteria Covered ............................................................................. 8

3.4 NCHC Additional Criteria Covered ............................................................................... 8

4.0 When the Procedure, Product, or Service Is Not Covered ..................................................... 9

4.1 General Criteria Not Covered .......................................................................................... 9

4.2 Specific Criteria Not Covered .......................................................................................... 9

4.2.1 Specific Criteria Not Covered by both Medicaid and NCHC ...................................... 9

4.2.2 Medicaid Additional Criteria Not Covered ................................................................... 9

4.2.3 NCHC Additional Criteria Not Covered ..................................................................... 10
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.0</td>
<td>Requirements for and Limitations on Coverage</td>
<td>10</td>
</tr>
<tr>
<td>5.1</td>
<td>Prior Approval</td>
<td>10</td>
</tr>
<tr>
<td>5.2</td>
<td>Prior Approval Requirements</td>
<td>10</td>
</tr>
<tr>
<td>5.2.1</td>
<td>General</td>
<td>10</td>
</tr>
<tr>
<td>5.2.2</td>
<td>Specific</td>
<td>10</td>
</tr>
<tr>
<td>5.3</td>
<td>Additional Limitations or Requirements</td>
<td>10</td>
</tr>
<tr>
<td>6.0</td>
<td>Provider(s) Eligible to Bill for the Procedure, Product, or Service</td>
<td>11</td>
</tr>
<tr>
<td>6.1</td>
<td>Provider Qualifications and Occupational Licensing Entity Regulations</td>
<td>11</td>
</tr>
<tr>
<td>6.2</td>
<td>Provider Certifications</td>
<td>11</td>
</tr>
<tr>
<td>6.3</td>
<td>Compliance</td>
<td>11</td>
</tr>
<tr>
<td>7.0</td>
<td>Additional Requirements</td>
<td>12</td>
</tr>
<tr>
<td>7.1</td>
<td>Compliance</td>
<td>12</td>
</tr>
<tr>
<td>8.0</td>
<td>Policy Implementation and History</td>
<td>12</td>
</tr>
</tbody>
</table>

**Attachment A: Claims-Related Information**

- A. Claim Type | 13
- B. International Classification of Diseases, Tenth Revisions, Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS) | 13
- C. Code(s) | 13
- D. Modifiers | 15
- E. Billing Units | 15
- F. Place of Service | 15
- G. Co-payments | 16
- H. Reimbursement | 16

**Attachment B: Drug Class Listing** | 16
Related Clinical Coverage Policies
Refer to https://dma.ncdhhs.gov/ for the related coverage policies listed below:
1A-41 Office Based Opioid Treatment: Use of Buprenorphine and Buprenorphine-Naloxone
1S-3 Laboratory Services
Pharmacy Prior Approval and Renewal Criteria located at https://www.nctracks.nc.gov

1.0 Description of the Procedure, Product, or Service
Various strategies are available to monitor beneficiaries receiving treatment for chronic pain or substance use disorders, and multicomponent interventions are often used. Many settings require a beneficiary to sign a contract before he or she is given a prescription for opioids. The contract generally involves obtaining a beneficiary’s agreement on behaviors he or she shall engage in during the treatment period (taking medication as prescribed) and not engage in (selling prescribed medication or obtaining additional prescriptions from other physicians).

Per an evidence assessment by the American Society of Interventional Pain Physicians (ASIPP), approximately one-third of patients with chronic pain either do not use opioids as prescribed or use them inappropriately. Studies also report that a substantial proportion of chronic pain patients inaccurately report adherence to prescribed medications and do not report use of illicit drugs.

Confirming whether a beneficiary follows office guidelines can pose a challenge. Risk-assessment screening instruments can aid in the assessment of a beneficiary’s risk for illicit substance use or misuse of prescription medications.

Another strategy for monitoring patients is testing of specimens for the presence or absence of drugs. Currently, urine is the most commonly tested sample. Advantages of urine sampling are that it is readily available, and standardized techniques for detecting drugs in urine exist. Blood, oral fluids, hair and sweat testing may gain in popularity over time as techniques for collecting and analyzing these specimens become more standardized. Currently, drug testing is allowed only from one source per day.

Immunooassay (IA) tests are used for screening and are performed either in a laboratory or in a provider’s office and use antibodies to detect a particular drug or drug metabolite in a sample. Immunooassay tests vary in the type of compounds they can detect. Some detect specific drugs and may fail to recognize similarly structured drugs within the same class. Other immunooassays identify only classes of drugs and thus results cannot be used to determine which drug a patient is taking. The degree of cross reactivity varies widely among immunooassays.

Immunooassay findings are generally reported presumptively as either positive (drug level above a pre-specified threshold) or negative (drug level below a pre-specified threshold). Raising or lowering the threshold thus changes the proportion of positive tests. A negative test is interpreted as a level below the threshold, and does not necessarily mean that the drug or metabolite is absent. Immunooassays generally have a rapid turnaround time, within minutes for onsite tests and one (1) to four (4) hours for laboratory-based tests.
Definitive drug tests are always performed in a laboratory. Definitive tests confirm the presence of a specific drug identified by a screening test and identify drugs that cannot be isolated by currently available immunoassays. There may be a several day turnaround time for definitive testing.

1.1 Definitions

1.1.1 Aberrant Behavior
An action or attitude that breaches mutually established medical boundaries such as ongoing illicit substance use, diversion, missed appointments, request for early refills, altering prescriptions, using an alternate route for medication administration, resistance to medication change or decrease in dose, lost medications, or obtaining narcotics from multiple sources.

1.1.2 Abstinence
Continuous abstinence from the drug of choice and no use or asymptomatic use of other substances during a period of time.

1.1.3 Clinical Laboratory Improvement Amendments (CLIA)
Regulates laboratory testing and requires clinical labs to be certified by their state and the Centers for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing. There are multiple levels of CLIA certification available depending on the type of testing to be performed.

1.1.4 Definitive Urine Drug Test
Also known as quantitative or confirmatory testing, identifies specific medications, illicit substances, and metabolites. Results are typically reported in concentrations of nanograms per milliliter (ng/mL).

1.1.5 Gas chromatography/mass spectrometry (GC/MS)
Considered to be the criterion standard for confirmatory testing. This technique involves using GC to separate the analytes in a specimen and MS to identify the specific molecular structures of the drug and its metabolites. The tests are able to quantify the amount of drug or metabolite present in the urine sample. Results are reported as the specific levels of substances detected in the urine. GC/MS generally requires specification of the drug or drugs to be identified.

1.1.6 Immunoassay (IA)
Used primarily to identify the presence or absence of drugs or drug classes above a preset cutoff level with use of an antibody. This test is read with photometric technology.

1.1.7 Mass Spectrometry and Liquid Chromatography
Newer techniques used by some offices and most commercial laboratories combine the presumptive and definitive testing in a single step. This testing may include up to 50 tests from a single sample. This testing, when done for screening purposes only, is considered to be presumptive testing.

1.1.8 Point of Care Testing (POCT)
Used by clinicians caring for a beneficiary for immediate test results for the immediate management of the beneficiary’s care. This is an IA testing method consisting of cups,
dipsticks, cassettes, or strips and read by the human eye or instrument assisted direct optical observation.

1.1.9 Presumptive Urine Drug Test
Also known as qualitative testing, determines the presence or absence of a drug class in a urine sample and is reported as a positive, negative, or with a numerical value.

1.1.10 Reflex Testing
Testing performed in a laboratory that is performed after initial test results to identify further diagnostic information essential to the care of the beneficiary. This test is not based on a physician’s order, and testing performed to complete a physician’s order is not considered reflex testing.

1.1.11 Specimen Validity Test
Testing to ensure sample is unadulterated and may include pH (potential of hydrogen), specific gravity, or creatinine.

2.0 Eligibility Requirements

2.1 Provisions

2.1.1 General
(The term “General” found throughout this policy applies to all Medicaid and NCHC policies)

a. An eligible beneficiary shall be enrolled in either:
   1. the NC Medicaid Program (Medicaid is NC Medicaid program, unless context clearly indicates otherwise); or
   2. the NC Health Choice (NCHC is NC Health Choice program, unless context clearly indicates otherwise) Program on the date of service and shall meet the criteria in Section 3.0 of this policy.

b. Provider(s) shall verify each Medicaid or NCHC beneficiary’s eligibility each time a service is rendered.

c. The Medicaid beneficiary may have service restrictions due to their eligibility category that would make them ineligible for this service.

d. Following is only one of the eligibility and other requirements for participation in the NCHC Program under GS 108A-70.21(a): Children must be between the ages of 6 through 18.

2.1.2 Specific
(The term “Specific” found throughout this policy only applies to this policy)

a. Medicaid
   None Apply.

b. NCHC
   None Apply.
2.2 Special Provisions

2.2.1 EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age

a. 42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiary under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed practitioner).

This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his or her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary’s physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary’s right to a free choice of providers.

EPSDT does not require the state Medicaid agency to provide any service, product or procedure:

1. that is unsafe, ineffective, or experimental or investigational.
2. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider’s documentation shows that the requested service is medically necessary “to correct or ameliorate a defect, physical or mental illness, or a condition” [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary’s health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

b. EPSDT and Prior Approval Requirements

1. If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does NOT eliminate the requirement for prior approval.
2. IMPORTANT ADDITIONAL INFORMATION about EPSDT and prior approval is found in the NCTracks Provider Claims and Billing Assistance Guide, and on the EPSDT provider page. The Web addresses are specified below.
2.2.2 EPSDT does not apply to NCHC beneficiaries

2.2.3 Health Choice Special Provision for a Health Choice Beneficiary age 6 through 18 years of age

The Division of Medical Assistance (DMA) shall deny the claim for coverage for an NCHC beneficiary who does not meet the criteria within Section 3.0 of this policy. Only services included under the NCHC State Plan and the DMA clinical coverage policies, service definitions, or billing codes are covered for an NCHC beneficiary.

3.0 When the Procedure, Product, or Service Is Covered

Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age.

3.1 General Criteria Covered

Medicaid and NCHC shall cover the procedure, product, or service related to this policy when medically necessary, and:

a. the procedure, product, or service is individualized, specific, and consistent with symptoms or confirmed diagnosis of the illness or injury under treatment, and not in excess of the beneficiary’s needs;

b. the procedure, product, or service can be safely furnished, and no equally effective and more conservative or less costly treatment is available statewide; and

c. the procedure, product, or service is furnished in a manner not primarily intended for the convenience of the beneficiary, the beneficiary’s caretaker, or the provider.

3.2 Specific Criteria Covered

3.2.1 Specific criteria covered by both Medicaid and NCHC

Medicaid and NCHC shall cover drug testing for the treatment of substance use disorders or chronic pain up to the annual testing limits of up to twenty-four (24) presumptive tests and twenty-four (24) definitive tests per calendar year when the following criteria are met:

3.2.1.1 Toxicity

A beneficiary who presents to any clinical setting with symptoms of substance use toxicity is treated presumptively to stabilize the beneficiary while awaiting rapid, then definitive testing to determine the cause(s) of presentation. The need for definitive drug testing is based on presumptive screen findings, responses to medical interventions, and treatment plan.

A presumptive drug test may be performed, if deemed appropriate by the medical professional, as part of the evaluation and management of a beneficiary who presents with any one of the following:
a. Coma;
b. Altered mental status in the absence of a clinically defined toxic syndrome or toxidrome;
c. Severe or unexplained cardiovascular instability;
d. Unexplained metabolic or respiratory acidosis in the absence of a clinically defined toxic syndrome or toxidrome;
e. Seizures with an undetermined history;
f. To provide antagonist to a specific drug.

**Note:** The presumptive findings, definitive drug tests ordered, and reasons for the testing must be documented in the beneficiary’s health record.

### 3.2.1.2 Treatment of substance use disorder

#### a. Indications for Testing

Drug tests for beneficiaries diagnosed with a SUD must be performed at random intervals to properly manage and monitor the beneficiary’s care. Testing profiles must be determined by the provider based on the following beneficiary criteria:

1. History, physical examination, and previous laboratory findings;
2. Beneficiary report of use and prescribed medications;
3. Suspected misused substance(s);
4. Community usage; and
5. Substances that may present high risk for additive or synergistic interactions with prescribed medication such as benzodiazepines or alcohol.

The beneficiary’s health record must contain documentation of appropriate testing frequency based on the stage of treatment or recovery, rationale for all drug class(es) ordered, results of laboratory testing, and how the results are to be used to guide care for both presumptive and definitive drug testing.

#### b. Frequency of Testing

1. For a beneficiary with **zero (0) to thirty (30) consecutive days of abstinence**, presumptive and definitive drug testing is expected at a frequency not to exceed once per calendar week.
2. For a beneficiary with **thirty-one (31) to ninety (90) consecutive days of abstinence**, presumptive and definitive drug testing is expected at a frequency not to exceed twice per thirty (30) consecutive calendar days.
3. For a beneficiary with **greater than ninety (90) consecutive days of abstinence**, presumptive and definitive drug testing is expected at a frequency not to exceed once per thirty (30) consecutive calendar days.
3.2.1.3 Treatment of Chronic Pain

a. Indications for Testing
Medical necessity for drug testing must be beneficiary-specific and based on elements identified during clinical assessment. This information must be documented in the health record and consist of the following, at a minimum:

1. Complete history of pain;
2. Physical examination;
3. Previous laboratory findings;
4. Current treatment plan,
5. Prescribed medications; and

The beneficiary’s health record must contain documentation of appropriate testing frequency based on the stage of treatment or recovery, rationale for all drug class(es) ordered, results of laboratory testing, and how the results are to be used to guide care for both presumptive and definitive drug testing.

b. Frequency of Testing
Frequency of drug testing must be based on a complete clinical assessment of the beneficiary’s risk potential for abuse and diversion, using a validated risk assessment interview or questionnaire, along with the beneficiary’s response to prescribed medications and any side effects reported. Determination of risk is made by the provider and is based on interpretation of assessment tools used.

1. For a beneficiary classified as low-risk, random presumptive and definitive testing is expected at a frequency not to exceed one (1) to two (2) times every 365 consecutive days for prescribed medications, non-prescribed medications that may pose a safety risk if taken concomitantly with prescribed medication(s), and illicit substances based on beneficiary history, clinical presentation, and community usage.

2. For a beneficiary classified as moderate-risk, random presumptive and definitive testing is expected at a frequency not to exceed two (2) to four (4) times every 365 consecutive days for prescribed medications, non-prescribed medications that may pose a safety risk if taken concomitantly with prescribed medication(s), and illicit substances based on beneficiary history, clinical presentation, and community usage.

3. For a beneficiary classified as high-risk, random presumptive and definitive testing is expected at a frequency not to exceed one (1) to three (3) times every 90 consecutive days for prescribed medications, non-prescribed medications that may pose a safety risk if taken concomitantly with prescribed
medication(s), and illicit substances based on beneficiary history, clinical presentation, and community usage.

Note: Any additional definitive drug testing beyond the criteria listed above must be justified by the provider in the health record, and only for situations in which changes in prescribed medications may be required.

3.2.1.4 Reflex Testing

As reference laboratories do not have access to beneficiary health records, Medicaid and NCHC shall cover reflex testing in the following circumstances:

a. To verify a presumptive positive drug test using definitive methods before reporting the presumptive finding to the ordering provider and without an additional order from the provider; or

b. To confirm the absence of a prescribed medication when a negative result is obtained by presumptive drug testing in the laboratory for a prescribed medication listed by the ordering provider.

3.2.1.5 Direct to Definitive Testing

Medicaid and NCHC shall cover direct to definitive drug testing when the test is individualized to the beneficiary based on history of use and substance(s) likely to be present.

3.2.1.6 Definitive Testing to Confirm a Negative Presumptive Result

Medicaid and NCHC shall cover definitive testing to confirm a negative presumptive result for the following circumstances when accompanied by a physician order:

a. The presumptive result is inconsistent with a beneficiary’s self-report, presentation, medical history, or current prescribed medication plan;

b. Following a review of clinical findings, the provider suspects use a substance that is inadequately detected or not detected by a presumptive drug test; or

c. To rule out an error as the cause of a negative presumptive result.

3.2.1.7 Definitive Testing to Confirm a Presumptive Positive

Medicaid and NCHC shall cover definitive testing to confirm a positive presumptive result for the following circumstances when accompanied by a physician order:

a. When the presumptive result is inconsistent with the expected result, beneficiary self-report, presentation, medical history, or current medication plan.

3.3 Medicaid Additional Criteria Covered

None Apply.

3.4 NCHC Additional Criteria Covered

None Apply.
4.0 When the Procedure, Product, or Service Is Not Covered

Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age.

4.1 General Criteria Not Covered

Medicaid and NCHC shall not cover the procedure, product, or service related to this policy when:

a. the beneficiary does not meet the eligibility requirements listed in Section 2.0;

b. the beneficiary does not meet the criteria listed in Section 3.0;

c. the procedure, product, or service duplicates another provider’s procedure, product, or service; or

d. the procedure, product, or service is experimental, investigational, or part of a clinical trial.

4.2 Specific Criteria Not Covered

4.2.1 Specific Criteria Not Covered by both Medicaid and NCHC

Medicaid and NCHC shall not cover drug testing for opioid treatment and controlled substance monitoring for the following:

a. Reflex definitive drug testing when presumptive testing is performed at point of care as the provider may have sufficient information to manage the beneficiary’s care. If the provider is not satisfied with the presumptive testing, they must determine the clinical appropriateness of and order specific subsequent definitive testing;

b. Point of care testing at the provider’s office followed by presumptive IA testing in a reference lab;

c. Presumptive IA testing in the provider’s office, followed by an order for a presumptive test by a reference lab;

d. Reference laboratories performing and billing for an IA presumptive test prior to definitive testing, without a specific provider order for the presumptive testing;

e. IA testing used to confirm a presumptive result obtained by cups, dipsticks, cards, cassettes, or other IA testing methods;

f. Drug testing of two (2) different specimen types from the same beneficiary on the same date of service;

g. Testing for medico-legal or employment purposes or to protect a physician from drug diversion charges or malpractice; or

h. Specimen validity testing consisting of pH, specific gravity, oxidants, or creatinine.

Note: In addition to the above, Medicaid and NCHC shall not cover presumptive or definitive drug testing for the treatment of substance use disorder or chronic pain in excess of the annual limits listed in subsection 3.2.1.

4.2.2 Medicaid Additional Criteria Not Covered

None Apply
4.2.3 NCHC Additional Criteria Not Covered
a. NCGS § 108A-70.21(b) “Except as otherwise provided for eligibility, fees, deductibles, copayments, and other cost sharing charges, health benefits coverage provided to children eligible under the Program shall be equivalent to coverage provided for dependents under North Carolina Medicaid Program except for the following:
   1. No services for long-term care.
   2. No nonemergency medical transportation.
   3. No EPSDT.
   4. Dental services shall be provided on a restricted basis in accordance with criteria adopted by the Department to implement this subsection.”

5.0 Requirements for and Limitations on Coverage

Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age.

5.1 Prior Approval
a. Medicaid and NCHC shall not require prior approval for drug testing for opioid treatment and controlled substance monitoring.
b. Medicaid and NCHC shall require Pharmacy Prior Authorization for use of buprenorphine or buprenorphine-naloxone combination medication (refer to pharmacy prior approval and renewal criteria located at https://www.nctracks.nc.gov/); and
c. Medicaid and NCHC shall require Pharmacy Prior Authorization for use of opioids for chronic pain (refer to pharmacy prior approval and renewal criteria located at https://www.nctracks.nc.gov/).

Prior Approval signifies medical necessity only; it does not address the beneficiary’s eligibility or guarantee claim payment.

5.2 Prior Approval Requirements

5.2.1 General
The provider(s) shall submit to the Department of Health and Human Services (DHHS) Utilization Review Contractor the following:
a. the prior approval request; and
b. all health records and any other records that support the beneficiary has met the specific criteria in Subsection 3.2 of this policy.

5.2.2 Specific
None Apply

5.3 Additional Limitations or Requirements
None Apply.
6.0 Provider(s) Eligible to Bill for the Procedure, Product, or Service

To be eligible to bill for the procedure, product, or service related to this policy, the provider(s) shall:

a. meet Medicaid or NCHC qualifications for participation;

b. have a current and signed Department of Health and Human Services (DHHS) Provider Administrative Participation Agreement; and

c. bill only for procedures, products, and services that are within the scope of their clinical practice, as defined by the appropriate licensing entity.

6.1 Provider Qualifications and Occupational Licensing Entity Regulations

None Apply.

6.2 Provider Certifications

Medicaid and NCHC require all laboratories to have a valid CLIA certification number on file to receive reimbursement for any laboratory procedures. Physicians are reminded that they may only bill for those tests for which they are certified.

Providers who have questions regarding CLIA Certification may contact the Division of Health Service Regulation Acute and Home Care Licensure and Certification and CLIA Program.

Providers may also view information on the CMS website for CLIA and Categorization of Tests at: https://www.cms.gov/ Additional Requirements

Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age.

6.3 Compliance

Provider(s) shall comply with the following in effect at the time the service is rendered:

a. All applicable agreements, federal, state and local laws and regulations including the Health Insurance Portability and Accountability Act (HIPAA) and record retention requirements; and

b. All DMA’s clinical (medical) coverage policies, guidelines, policies, provider manuals, implementation updates, and bulletins published by the Centers for Medicare and Medicaid Services (CMS), DHHS, DHHS division(s) or fiscal contractor(s).

In addition to the above, provider(s) shall comply with the following:

a. 42 CFR Part §493 Laboratory Requirements;


c. NCAC 27G .3604(h) Random Testing;

d. NCAC 27G .3604 (k)(4) Diversion Control Plan; and

e. Policies of the North Carolina Medical Board.
7.0 Additional Requirements

*Note: Refer to Subsection 2.2.1 regarding EPSDT Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age.*

7.1 Compliance

Provider(s) shall comply with the following in effect at the time the service is rendered:

a. All applicable agreements, federal, state and local laws and regulations including the Health Insurance Portability and Accountability Act (HIPAA) and record retention requirements; and

b. All DMA’s clinical (medical) coverage policies, guidelines, policies, provider manuals, implementation updates, and bulletins published by the Centers for Medicare and Medicaid Services (CMS), DHHS, DHHS division(s) or fiscal contractor(s).

8.0 Policy Implementation and History

**Original Effective Date:** January 1, 2016

**History:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Section or Subsection Amended</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/01/2017</td>
<td>All Sections and Attachment(s)</td>
<td>New policy on drug testing for the treatment of substance use disorders and chronic pain</td>
</tr>
</tbody>
</table>
Attachment A: Claims-Related Information

Provider(s) shall comply with the, NCTracks Provider Claims and Billing Assistance Guide, Medicaid bulletins, fee schedules, DMA’s clinical coverage policies and any other relevant documents for specific coverage and reimbursement for Medicaid and NCHC:

A. Claim Type

Professional (CMS-1500/837P transaction)

Institutional (UB-04/837I transaction)

B. International Classification of Diseases, Tenth Revisions, Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS)

Provider(s) shall report the ICD-10-CM and Procedural Coding System (PCS) to the highest level of specificity that supports medical necessity. Provider(s) shall use the current ICD-10 edition and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for code description, as it is no longer documented in the policy.

<table>
<thead>
<tr>
<th>ICD-10-CM Code(s) Supporting Medical Necessity for Drug Testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>E87.2 M51.14 T39.2X2A T43.203A</td>
</tr>
<tr>
<td>F10.20 M51.15 T39.2X3A T43.204A</td>
</tr>
<tr>
<td>F11.10 M51.16 T39.2X4A T43.211A</td>
</tr>
<tr>
<td>F11.120 M51.17 T39.311A T43.212A</td>
</tr>
<tr>
<td>F11.129 M51.36 T39.312A T43.213A</td>
</tr>
<tr>
<td>F11.20 M51.37 T39.313A T43.214A</td>
</tr>
<tr>
<td>F11.220 M54.10 T39.314A T43.221A</td>
</tr>
<tr>
<td>F11.221 M54.14 T39.391A T43.222A</td>
</tr>
<tr>
<td>F11.222 M54.15 T39.392A T43.223A</td>
</tr>
<tr>
<td>F11.229 M54.16 T39.393A T43.224A</td>
</tr>
<tr>
<td>F11.23 M54.17 T39.394A T43.291A</td>
</tr>
<tr>
<td>F11.24 M54.18 T40.0X1A T43.292A</td>
</tr>
<tr>
<td>F11.250 M54.2 T40.0X2A T43.293A</td>
</tr>
<tr>
<td>F11.251 M54.5 T40.0X3A T43.294A</td>
</tr>
<tr>
<td>F11.259 M60.811 T40.0X4A T43.3X1A</td>
</tr>
<tr>
<td>F11.281 M60.812 T40.1X1A T43.3X2A</td>
</tr>
<tr>
<td>F11.282 M60.821 T40.1X2A T43.3X3A</td>
</tr>
<tr>
<td>F11.288 M60.822 T40.1X3A T43.3X4A</td>
</tr>
<tr>
<td>F11.29 M60.831 T40.1X4A T43.4X1A</td>
</tr>
<tr>
<td>F12.10 M60.832 T40.2X1A T43.4X2A</td>
</tr>
<tr>
<td>F13.10 M60.841 T40.2X2A T43.4X3A</td>
</tr>
<tr>
<td>F13.120 M60.842 T40.2X3A T43.4X4A</td>
</tr>
<tr>
<td>F13.129 M60.851 T40.2X4A T43.501A</td>
</tr>
<tr>
<td>F14.10 M60.852 T40.3X1A T43.502A</td>
</tr>
<tr>
<td>F14.120 M60.861 T40.3X2A T43.503A</td>
</tr>
<tr>
<td>F14.121 M60.862 T40.3X3A T43.504A</td>
</tr>
<tr>
<td>F14.129 M60.871 T40.3X4A T43.591A</td>
</tr>
<tr>
<td>F14.180 M60.872 T40.4X1A T43.592A</td>
</tr>
<tr>
<td>Code</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>F15.10</td>
</tr>
<tr>
<td>F15.120</td>
</tr>
<tr>
<td>F15.129</td>
</tr>
<tr>
<td>F18.10</td>
</tr>
<tr>
<td>F18.120</td>
</tr>
<tr>
<td>F18.90</td>
</tr>
<tr>
<td>F19.10</td>
</tr>
<tr>
<td>F19.120</td>
</tr>
<tr>
<td>F19.129</td>
</tr>
<tr>
<td>F19.20</td>
</tr>
<tr>
<td>F20.0</td>
</tr>
<tr>
<td>F20.1</td>
</tr>
<tr>
<td>F20.2</td>
</tr>
<tr>
<td>F20.89</td>
</tr>
<tr>
<td>F55.0</td>
</tr>
<tr>
<td>F55.1</td>
</tr>
<tr>
<td>F55.2</td>
</tr>
<tr>
<td>F55.3</td>
</tr>
<tr>
<td>F55.4</td>
</tr>
<tr>
<td>F55.8</td>
</tr>
<tr>
<td>G40.301</td>
</tr>
<tr>
<td>G40.309</td>
</tr>
<tr>
<td>G40.311</td>
</tr>
<tr>
<td>G40.319</td>
</tr>
<tr>
<td>G40.401</td>
</tr>
<tr>
<td>G40.409</td>
</tr>
<tr>
<td>G40.411</td>
</tr>
<tr>
<td>G40.419</td>
</tr>
<tr>
<td>G40.901</td>
</tr>
<tr>
<td>G40.909</td>
</tr>
<tr>
<td>G40.911</td>
</tr>
<tr>
<td>G40.919</td>
</tr>
<tr>
<td>G89.29</td>
</tr>
<tr>
<td>G89.4</td>
</tr>
<tr>
<td>I44.0</td>
</tr>
<tr>
<td>I44.1</td>
</tr>
<tr>
<td>I44.30</td>
</tr>
<tr>
<td>I45.81</td>
</tr>
<tr>
<td>I47.0</td>
</tr>
<tr>
<td>I47.1</td>
</tr>
<tr>
<td>I47.2</td>
</tr>
<tr>
<td>I49.2</td>
</tr>
<tr>
<td>M25.50</td>
</tr>
<tr>
<td>M47.21</td>
</tr>
<tr>
<td>M47.22</td>
</tr>
<tr>
<td>M47.23</td>
</tr>
<tr>
<td>M47.26</td>
</tr>
<tr>
<td>M47.27</td>
</tr>
<tr>
<td>M47.28</td>
</tr>
</tbody>
</table>
C. Code(s)

Provider(s) shall report the most specific billing code that accurately and completely describes the procedure, product or service provided. Provider(s) shall use the Current Procedural Terminology (CPT), Health Care Procedure Coding System (HCPCS), and UB-04 Data Specifications Manual (for a complete listing of valid revenue codes) and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for the code description, as it is no longer documented in the policy.

If no such specific CPT or HCPCS code exists, then the provider(s) shall report the procedure, product or service using the appropriate unlisted procedure or service code.

Unlisted Procedure or Service

CPT: The provider(s) shall refer to and comply with the Instructions for Use of the CPT Codebook, Unlisted Procedure or Service, and Special Report as documented in the current CPT in effect at the time of service.

HCPCS: The provider(s) shall refer to and comply with the Instructions For Use of HCPCS National Level II codes, Unlisted Procedure or Service and Special Report as documented in the current HCPCS edition in effect at the time of service.

D. Modifiers

Provider(s) shall follow applicable modifier guidelines.

E. Billing Units

Provider(s) shall report the appropriate code(s) used which determines the billing unit(s).

CPT codes for presumptive or definitive testing will not be recognized when there is an active HCPCS code. There is a limit of one presumptive and one definitive test per beneficiary, per date of service regardless of the number of providers billing for the service.

F. Place of Service

Office, outpatient, laboratory
G. Co-payments


H. Reimbursement

Provider(s) shall bill their usual and customary charges.
For a schedule of rates, refer to: http://dma.ncdhhs.gov/

---

**Attachment B: Drug Class Listing**

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>Acetone, ethanol, ethchlorvynol, ethylene glycol, isopropanol, isopropyl alcohol, methanol, ethanol conjugates</td>
</tr>
<tr>
<td>Alcohol Biomarkers</td>
<td>ethanol conjugates</td>
</tr>
<tr>
<td>Alkaloids, not otherwise specified</td>
<td>7-Hydroxymitragynine, atropine, cotinine, lysergic acid diethylamide, mescaline, mitragynine, nicotine, psilocin, psilocybin, scopolamine</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>Amphetamine, methamphetamine, ephedrineisdexamphetamine, phentermine, phenylethanolamine, pseudoephedrine</td>
</tr>
<tr>
<td>Anabolic Steroids</td>
<td>1- Androstenediol, 1-androstenedione, 1-testosterone, 4-hydroxy-tetosterone, 6-oxo, 19-norandrostenedione, androstenedione, androstanolone, bolandiol, bolasterone, boldenone, boldione, calusterone, closebol, danazol, dehydrochlormethytestosterone, dihydrotestosterone, drostanolone, epiandrosterone, epitestosterone, fluoxymesterone, furazabol, mesterolone, mesterolone, methandienone, methandriol, methenolone, methyldienolone, methyl-1-testosterone, methylnortestosterone, methyltestosterone, mibolerone, nandrolone, norbolethone, norclostebol, noretandrolone, norethindrone, oxabolone, oxandrolone, oxymesterone, oxymetholone, stanozolol, syenbolone, tibolone, trenbolone, zeranol</td>
</tr>
<tr>
<td>Analgesics, non-opioid</td>
<td>Acetaminophen, diclofenac, ibuprofen, ketoprofen, naproxen, oxaprozin, salicylate</td>
</tr>
<tr>
<td>Antidepressants, serotonergic class</td>
<td>Citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline</td>
</tr>
<tr>
<td>Antidepressants, tricyclic and other cyclicals</td>
<td>Amitriptyline, amoxapine, clomipramine, demexiptiline, desipramine, doxepin, imipramine, maprotiline, mirtazapine, nortriptyline, protriptyline</td>
</tr>
</tbody>
</table>
### Antidepressants, not otherwise specified
- Bupropion, desvenlafaxine, isocarboxaxid, nefazodone, phenelzine, selegiline, tranylcypromine, trazadone, venlafaxine

### Antiepileptics, not otherwise specified
- Carbamazepine, clobazam, dimethadone, ethosuximide, ezogabine, lamotrigine, levetiracetam, methsuximide, oxcarbazepine, phenytoin, primidone, rufinamide, tiagabine, topiramate, trimethadione, valproic acid, zonisamide

### Antipsychotics, not otherwise specified
- Aripiprazole, chlorpromazine, clozapine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, olanzapine, paliperidone, perphenazine, phenothiazine, pimozide, prochlorperazine, quetiapine, risperidone, trifluoperazine, thiothixene, thioridazine, ziprasidone

### Barbiturates
- Amobarbital, aprobarbital, butabital, cyclobarbital, mephobarbital, pentobarbital, phenobarbital, secobarbital, talbutal, thiopental

### Benzodiazepines
- Alpha-hydroxyalprazolam, alprazolam, chlordiazepoxide, clonazepam, chlorzepate, diazepam, estazolam, flunitrazepam, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, 7-Aminoclonazepam

### Buprenorphine
- Buprenorphine

### Cannabinoids, Natural
- Marijuana, dronabinol carboxy-THC

### Cannabinoids, Synthetic

### Cocaine
- Benzoylecgonine, cocaethylene, cocaine, ecgonine methyl ester, norcocaine

### Fentanyl
- Acetylfentanyl, alfentanil, fentanyl, remifentanil, sufentanil

### Gabapentin
- Gabapentin

### Heroin Metabolite
- 6-acetylmorphine, acetylcodeine, diacetylmorphine

### Ketamine
- Ketamine, norketamine

### Methadone
- Methadone, EDDP

### Methylenedioxymethylmethcathinones
- MDA, MDEA, MDMA

### Methylenedioxyamphetamine Analogs
- MDA, MDEA, MDMA

### Methyphenidate
- Methyphenidate, ritalinic acid

### Opiates
- Codeine, dihydrocodeine, hydrocodone, hydromorphone, morphine

### Opioids and Opioid Analogs
- Butorphanol, desomorphine, dextromethorphan, dextrophan, levorphanol, meperidine, mepoxide, naltrexone, normeperidine, pentazocine

### Oxycodone
- Oxycodone, oxymorphone

### Phencyclidine
- Phencyclidine

### Pregabalin
- Pregabalin

### Propoxyphene
- Norprooxyphene, propoxyphene

### Sedative Hypnotics
- Eszopiclone, zaleplon, zolpidem

### Skeletal Muscle Relaxants
- Baclofen, carisoprodol, cyclobenzaprine, meprobamate, metaxalone, methocarbamol, orphenadrine, tizanidine

### Stimulants, Synthetic
- 2C-B, 2C-E, 2C-I, 2C-H, 3TFMPP, 4-methylcathinone, alpha-PVP, benzylpiperazine, bromodragonfly, cathinone, m-CPP, MDPBP, MDPV, mephedrone, methcathinone, methylone, phenethamines, salvinorin, tryptamines

### Tapentadol
- Tapentadol

### Tramadol
- Tramadol
<table>
<thead>
<tr>
<th>NC Division of Medical Assistance</th>
<th>Medicaid and Health Choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Testing for Opioid Treatment and</td>
<td>Clinical Coverage Policy No: 1S-8</td>
</tr>
<tr>
<td>Controlled Substance Monitoring</td>
<td>Effective Date: November 1, 2017</td>
</tr>
</tbody>
</table>